雷珠单抗联合曲安奈德治疗湿性年龄相关性黄斑变性的疗效及对白介素的影响

doi:10.3760/cma.j.cn115909-20190821-00231

摘要
图/表
参考文献(17)
相关文章 (15)

全文: PDF 827KB HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：观察雷珠单抗联合曲安奈德治疗湿性年龄相关性黄斑变性（AMD）的临床疗效，并探讨该疗法对白介素（IL）-1β、IL-2、IL-6、IL-8水平的影响。方法：前瞻性研究。选取2017年11月至2018 年10月内蒙古包钢医院收治的86例（102眼）湿性AMD患者，采用随机数表法分为雷珠单抗组（43 例，50眼）和联合组（43例，52眼），雷珠单抗组患者实施玻璃体腔注射雷珠单抗治疗，联合组在雷珠单抗组基础上加用曲安奈德治疗。比较2组治疗前，治疗后2周、1个月及3个月眼压值；比较2组治疗前，治疗后1、3、6个月黄斑中心凹厚度（CMT）及视力变化；比较2组治疗前、治疗后1个月血清IL-1β、IL-2、IL-6、IL-8水平；对治疗期间2组并发症发生情况。采用t检验、重复测量方差分析及χ2 检验对数据进行分析。结果：2组患者眼压值比较，差异无统计学意义（F组间=1.275，P=0.496； F时间=1.810，P=0.211；F交互=1.772，P=0.335）；治疗前2 组CMT、视力比较，差异无统计学意义（t=0.042，P=0.967；t=0.720，P=0.473）；治疗后1、3、6个月，联合组CMT均低于雷珠单抗组（t=2.086， P=0.039；t=3.398，P=0.001；t=2.987，P=0.004），视力均高于雷珠单抗组（t=3.265，P=0.001；t=2.217， P=0.029；t=2.519，P=0.013）；随着治疗时间的延长，2组CMT均呈降低趋势（t治疗前vs.治疗后1个月=6.210、 4.218，P<0.001；t治疗后1个月vs.治疗后3个月=16.772、15.865，P<0.001；t治疗后3个月vs.治疗后6个月=4.472、4.848， P<0.001），视力呈升高趋势（t治疗前vs.治疗后1个月=4.527、8.395，P<0.001；t治疗后1个月vs.治疗后3个月=5.369、5.349， P<0.001；t治疗后3个月vs.治疗后6个月=3.335、3.730，P<0.001）；与治疗前相比，治疗后1个月2组血清IL-1β、 IL-6、IL-8水平均降低（t联合组=10.544、32.169、33.156，均P<0.001；t雷珠单抗组=8.996、25.687、30.754，均P<0.001），且联合组低于雷珠单抗组（t=2.894，P=0.005；t=5.997，P<0.001；t=3.934，P<0.001）；与治疗前相比治疗后3个月2组血清IL-2水平均升高（t=20.067、9.091，均P<0.001），且联合组高于雷珠单抗组（t=7.705，P<0.001）；2组出血、眼内异物感、一过性眼压升高发生率及并发症总发生率比较，差异均无统计学意义（校正χ2 =0.001，P=0.972；校正χ2 =0.221，P=0.638；Fisher精确检验P=0.116；校正χ2 =0.004，P=0.951）。结论：玻璃体腔注射雷珠单抗联合曲安奈德可有效改善湿性AMD视觉功能，降低CMT及血清IL-1β、IL-6、IL-8水平，增加血清IL-2水平，缓解炎症反应程度。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：雷珠单抗, 曲安奈德, 年龄相关性黄斑变性, 白介素

Abstract：Objective: To observe the clinical efficacy of Ranibizumab combined with Triamcinolone acetonide in the treatment of wet age-related macular degeneration (AMD), and to explore its effects on interleukin (IL)-1β, IL-2, IL-6. The impact of IL-8 levels. Methods: This is a retrospective study. A total of 86 cases (102 eyes) of wet AMD patients admitted to Inner Mongolia Baogang Hospital from November 2017 to October 2018 were randomly divided into Ranibizumab group (43 cases, 50 eyes) and combination group (43 cases, 52 eyes). The patients in the Ranibizumab group were treated with intravitreal injection of Ranibizumab, and the combined group was treated with Triamcinolone acetonide with the same method on the basis of intravitreal injection of Ranibizumab. The intraocular pressure values of the two groups before treatment, 2 weeks, 1 month and 3 months after treatment were compared. The central retinal thickness (CMT) and visual acuity of the two groups before treatment, 1 month, 3 months and 6 months after treatment were compared. The serum levels of IL-1β, IL-2, IL-6 and IL-8 were compared between the two groups before treatment and 1 month after treatment. The complications during treatment were counted and compared. Two-sample measurement data using t test. Repeated measurement variance analysis using repeated measurement data, further comparison using LSD-t test. χ 2 test was used for two count sample data. Results: There were no significant differences between the two groups (Fgroups=1.275, P=0.496; Ftime=1.810, P=0.211; Finteraction=1.772, P=0.335). There was no significant difference in CMT and visual acuity between the two groups before treatment (t=0.042, P=0.967; t=0.720, P=0.473). At one month, three months and six months after treatment, CMT of combined group was lower than that of Ranibizumab group (t=2.086, P=0.039; t=3.398, P=0.001; t=2.987, P=0.004), and visual acuity of combined group was higher than that of Ranibizumab group at different time (t=3.265, P=0.001; t=2.217, P=0.029; t=2.519, P=0.013). The CMT decreased (tbefore treatment vs. 1 month after treatment=6.210, 4.218, P<0.001; t1 month after treatment vs. 3 months after treatment=16.772, 15.865, P<0.001; t3 months after treatment vs. 6 months after treatment=4.472, 4.848, P<0.001) and visual acuity increased (tbefore treatment vs. 1 month after treatment=4.527, 8.395, P<0.001; t1 month after treatment vs. 3 months after treatment=5.369, 5.349, P<0.001; t3 months after treatment vs. 6 months after treatment=3.335, 3.730, P<0.001) with time in both groups. Compared with before treatment, the serum levels of IL-1β, IL-6 and IL-8 in 1 month after treatment were lower in the 2 groups (tcombined group=10.544, 32.169, 33.156, all P<0.001; tRanibizumab group=8.996, 25.687, 30.754, all P<0.001), and the combined group were lower than those in the Ranibizumab group (t=2.894, P=0.005; t=5.997, P<0.001; t=3.934, P<0.001). Compared with before treatment, the serum IL-2 level in the 2 groups were higher that 3 months after treatment (t=20.067, 9.091, all P<0.001), and the combined group was higher than that in the Ranibizumab group (t=7.705, P<0.001). There were no significant difference in the rates of bleeding, intraocular foreign body sensation, transient intraocular hypertension and total complications between the two groups (correction χ2 =0.001, P=0.972; correction χ2 =0.221, P=0.638; Fisher's exact test P=0.116; correction χ2 =0.004, P=0.951). Conclusions: Intravitreal injection of Ranibizumab combined with triamcinolone acetonide can effectively improve the visual function of wet AMD, reduce CMT, relieve inflammation, and it is safe and reliable.

Key words： Ranibizumab triamcinolone acetonide age-related macular degeneration interleukin

收稿日期: 2019-08-21

基金资助:国家自然科学基金（81770952）

通讯作者: 辛向阳（ORCID：0000-0002-9819-168X），Email：bgyy_yk@163.com

引用本文:

盛小红1 辛向阳1 王利明1 孙妍1 李晓华2. 雷珠单抗联合曲安奈德治疗湿性年龄相关性黄斑变性的疗效及对白介素的影响[J]. 中华眼视光学与视觉科学杂志, 2020, 22(5): 341-346. Xiaohong Sheng1,Xiangyang Xin1,Liming Wang1,Yan Sun1,Xiaohua Li2. Therapeutic Effect of Ranibizumab Combined with Triamcinolone Acetonide on Wet Age-Related Macular Degeneration and Its Effect on Interleukin. Chinese Journal of Optometry Ophthalmology and Visual science, 2020, 22(5): 341-346. DOI: 10.3760/cma.j.cn115909-20190821-00231

链接本文:

https://www.cjoovs.com/CN/10.3760/cma.j.cn115909-20190821-00231 或 https://www.cjoovs.com/CN/Y2020/V22/I5/341

[1]	Jin G, Ding X, Xiao W, et al. Prevalence of age-related macular degeneration in rural southern China: The Yangxi Eye Study. Br J Ophthalmol, 2018, 102(5): 625-630. DOI:10.1136/ bjophthalmol-2017-310368.
[2]	牟佳, 周思睿, 刘依琳, 等. 年龄相关性黄斑变性临床诊疗思路: 浅析诊疗指南. 中国医师杂志, 2018, 20(8): 1123-1127, 1131. DOI: 10.3760/cma.j.issn.1008-1372.2018.08.002.
[3]	蒋璐, 陶继伟, 洪明胜, 等. 光动力学疗法联合雷珠单抗对比雷珠单抗治疗湿性AMD有效性和安全性的Meta分析. 中华眼视光学与视觉科学杂志, 2014, 16(8): 493-499. DOI: 10.3760/cma.j.issn.1674-845X.2014.08.011.
[4]	Pitarokoili K, Sgodzai M, Grüter T, et al. Intrathecal triamcinolone acetonide exerts anti-inflammatory effects on Lewis rat experimental autoimmune neuritis and direct antioxidative effects on Schwann cells. J Neuroinflammation, 2019, 16(1): 58. DOI: 10.1186/s12974-019-1445-0.
[5]	美国眼科学会. 眼科临床指南. 2版. 北京: 人民卫生出版社, 2013: 155-156.
[6]	Pariente A, Peláez R, Pérez-Sala á, et al. Inflammatory and cell death mechanisms induced by 7-ketocholesterol in the retina. Implications for age-related macular degeneration. Exp Eye Res, 2019, 187: 107746. DOI: 10.1016/j.exer.2019.107746.
[7]	Stavrev VN, Sivkova NP, Koleva-Georgieva DN. Optical Coherence tomography-angiography of different choroidal neovascularization subtypes in wet age-related macular degeneration. Folia Med (Plovdiv), 2019, 61(2): 317-326. DOI: 10.2478/folmed-2018-0061.
[8]	Keenan TD, Vitale S, Agrón E, et al. Visual acuity outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Age-related eye disease study 2 report number 19. Ophthalmol Retina, 2019, 4(1): 3-12. DOI: 10.1016/j.oret.2019.06.001.
[9]	王彦荣, 李海辉, 顾莉莉. 玻璃体腔注射雷珠单抗对湿性年龄相关性黄斑变性患者视觉功能和血清VEGF含量的影响. 解放军医药杂志, 2017, 29(10): 80-83. DOI: 10.3969/j.issn.2095-140X. 2017.10.020.
[10]	Baek J, Lee JH, Jung BJ, et al. Morphologic features of large choroidal vessel layer: age-related macular degeneration, polypoidal choroidal vasculopathy, and central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol, 2018, 256(12): 2309-2317. DOI: 10.1007/s00417-018-4143-1.
[11]	Sharma S, Khan MA, Chaturvedi A, et al. Real-life clinical effectiveness of Razumab? (the World's First Biosimilar of Ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT Study. Ophthalmologica, 2019, 241(1): 24-31. DOI: 10.1159/000488602.
[12]	Campochiaro PA, Wykoff CC, Brown DM, et al. Suprachoroidal Triamcinolone acetonide for retinal vein occlusion: Results of the Tanzanite Study. Ophthalmol Retina, 2018, 2(4): 320-328. DOI: 10.1016/j.oret.2017.07.013.
[13]	Chen J, Cong X, Zhan X, et al. Effects of Parecoxib on pain threshold and inflammatory factors IL-1β, IL-6 and TNF-α in spinal cord of rats with bone cancer pain. J Coll Physicians Surg Pak, 2019, 29(6): 528-531. DOI: 10.29271/jcpsp.2019.06.528.
[14]	华红霞, 任国琴, 孙优苗, 等. 香菇多糖对老年乳腺癌化疗病人T细胞亚群及血清IL-2、IL-6的影响. 实用老年医学, 2017, 31(2): 157-160. DOI: 10.3969/j.issn.1003-9198.2017.02.016.
[15]	Ten Berge JC, Fazil Z, van den Born I, et al. Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and cataract. Acta Ophthalmol, 2019, 97(2): 185-192. DOI: 10.1111/aos.13899.
[16]	Motohashi R, Noma H, Yasuda K, et al. Dynamics of Inflammatory factors in aqueous humor during Ranibizumab or Aflibercept treatment for age-related macular degeneration. Ophthalmic Res, 2017, 58(4): 209-216. DOI: 10.1159/000478705.
[17]	赵雁焕, 徐梅, 陆洋. 丹参注射液联合曲安奈德局部注射治疗OSF的疗效及对血清TGF-β1、IL-6的影响. 海南医学院学报, 2017, 23(5): 673-675, 679. DOI: 10.13210/j.cnki.jhmu. 20161221.019.